US › Healthcare

MacroGenics Inc (MGNX)

US · Healthcare · Biotechnology

$3.90+2.09%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$20.8M
Revenue YoY
+57.5%
Net profit
$-36.8M
Profit YoY
+10.4%
EPS
$-0.58
EPS estimate
$-0.55
Net margin
-177.0%

EPS came in at -0.58 against a street estimate of -0.55 — a miss of 5.5%.

Key statistics

Market cap
$234.5M
Forward P/E
61.0
P/B
11.06
Book value
$0.33
EPS (TTM)
$-1.11
52-week high
$5.08
52-week low
$1.29
50-day MA
$4.27
200-day MA
$2.72
Beta
1.18

Analyst view

Analysts rate MacroGenics Inc a buy (3 buy, 4 hold, 0 sell out of 7) with an average price target of $6.75.

Shareholding

Insiders
3.43%
Institutions
69.44%

Largest institutional holders

FundStake
Armistice Capital, LLC9.46%
Renaissance Technologies Corp4.66%
Millennium Management LLC4.40%
Vanguard Capital Management, LLC4.18%
Acadian Asset Management LLC4.00%
Two Sigma Investments LLC3.98%
Bank of America Corp3.78%
Marshall Wace Asset Management Ltd3.19%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for MacroGenics Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.